(UroToday.com) The 2024 IBCN annual meeting included a session on novel therapies and outcome measures in clinical trials, featuring a presentation by Dr. Andrea Necchi discussing the interim analysis of SunRISe-4, assessing TAR-200 + cetrelimab or cetrilumab alone as neoadjuvant therapy in patients with muscle-invasive bladder cancer. A standard of care approach for muscle-invasive bladder cancer (cT2-T4aN0M0) includes radical cystectomy with or without neoadjuvant chemotherapy. However, up to 50% of patients with muscle-invasive bladder cancer are ineligible for neoadjuvant chemotherapy. Approximately 50% of patients experience recurrence within two years of radical cystectomy, and the 5-year survival after radical cystectomy is ~ 50%.
In patients with muscle-invasive bladder cancer undergoing a radical cystectomy, pathologic stage is a prognostic factor for survival. Pathologic complete response rates with radical cystectomy alone, with neoadjuvant chemotherapy, and with neoadjuvant checkpoint inhibitors are 10–15%, ~40%, and 31–39%, respectively. A pathologic complete response in patients who have received neoadjuvant chemotherapy is associated with a 55% lower risk of death and an 81% lower risk of recurrence compared to patients with residual disease. Thus, there is a high unmet need for effective and more tolerable treatment options for patients with muscle-invasive bladder cancer who are candidates for radical cystectomy, but not candidates for or who refuse neoadjuvant chemotherapy.
TAR-200 is a gemcitabine intravesical releasing system designed to provide sustained gemcitabine within the bladder. Phase I studies have shown clinical activity for TAR-200 in muscle-invasive bladder cancer patients:
Cetrelimab is an anti-PD-1 agent. SunRISe-4 is an ongoing randomized phase II study assessing the efficacy and safety of neoadjuvant TAR-200 + cetrelimab or cetrelimab monotherapy in patients with muscle-invasive bladder cancer scheduled for radical cystectomy and who are ineligible for or refuse neoadjuvant chemotherapy.
The key trial eligibility criteria were as follows:
- cT2-4aN0M0 muscle-invasive bladder cancer
- Predominant urothelial carcinoma histology
- Ineligible for or refusing neoadjuvant chemotherapy
ECOG performance status 0–1
Patients underwent 5:3 randomization to:
- TAR-200 225 mg gemcitabine every 3 weeks (indwelling) for 12 weeks + cetrelimab intravenously for 12 weeks (4 cycles)
- Cetrelimab intravenously for 12 weeks (4 cycles)
Randomization was stratified by the absence or presence of visible residual disease at TURBT and tumor stage at muscle-invasive bladder cancer diagnosis (cT2 versus cT3-4a). The planned sample size was n=160, and the primary endpoint was a pathologic complete response. Key secondary endpoints were recurrence-free survival, safety, pathologic objective response (i.e., ≤ypT1N0), and overall survival. For this interim analysis, the clinical data cutoff was May 31, 2024. The trial design for SunRISe-4 is as follows:
The statistical plan is summarized as follows:
Dr. Necchi highlighted that this is not a comparative trial. The goal is to describe the efficacy outcomes in each arm without directly comparing them. The interim analysis for this report was presented after the first 80 participants completed their radical cystectomy. The efficacy evaluable patients for this report were those who had adequate radical cystectomy results or who had radiographic progression or death prior to radical cystectomy.
A total of 122 patients were randomized, 80 to Cohort 1 of TAR-200 + cetrelimab and 42 to Cohort 2 of cetrelimab monotherapy. The efficacy evaluable population included 53 and 31 patients from Cohorts 1 and 2, respectively:
Cisplatin ineligibility was present in 37–39% of patients, and 15–20% had residual disease on TURBT. Overall, 79–85% of patients had cT2 disease at diagnosis, variant histology was present in 20–27% of tumors, and 13–20% had received prior intravesical therapy:
The pathologic complete response in the combination arm was 42%, and the pathologic objective response (pathologic complete response + ≤ypT1N0) was 60%. The corresponding proportions in the cetrelimab monotherapy arm were 23% and 36%, respectively:
These outcomes were assessed, stratified by clinical stage, and completeness of TURBT. In cT2 patients, the pathologic complete response and pathologic objective response rates were 48% and 68% respectively. Conversely, in cT3-4a patients, the corresponding rates were lower at 23% and 39%, respectively. Patients with an incomplete TURBT (n = 9 only) had pathologic complete response and pathologic objective response rates of 56% and 67%, respectively. Those with a complete TURBT had rates of 39% and 59%, respectively:
The corresponding rates by clinical stage and TURBT completeness in the cetrelimab monotherapy arm are summarized below:
The efficacy of TAR-200 improved with an increasing number of doses administered. The pathologic complete response proportion increased from 27% to 30% to 50% in patients who received 1–2, 3, and the full 4 doses, respectively:
Immune-related grade ≥3 adverse events were observed in 6.3% of patients in the TAR-200 + cetrelimab arm and 5% of patients in the cetrelimab monotherapy arm. Overall, grade ≥3 treatment-related adverse events were observed in 11.4% and 5% of patients in the combination and monotherapy arms, respectively. Adverse events leading to treatment discontinuation were observed in 13% of patients in the combination arm and none in the monotherapy arm. The median time to radical cystectomy was 13.7 weeks in the combination arm and 12.6 weeks in the monotherapy arm:
Dr. Necchi concluded his presentation discussing the interim analysis of SunRISe-4 with the following take-home points:
- The combination of neoadjuvant TAR-200 + cetrelimab showed pathologic complete response and pathologic objective response rates of 42% and 60%, respectively, in patients with muscle-invasive bladder cancer
- In the cT2 subgroup, 48% of patients treated with TAR-200 + cetrelimab achieved pathologic complete response, and 68% were downstaged to ≤pT1 at radical cystectomy
- Cetrelimab monotherapy provided pathologic complete response and pathologic objective response rates of 23% and 35%, respectively.
- TAR-200 + cetrelimab had a manageable safety profile in the neoadjuvant setting
- Most treatment-related adverse events with TAR-200 + cetrelimab were low-grade
- The rate of discontinuations due to treatment-related adverse events was low at 13%
- SunRISe-4 demonstrates for the first time a benefit of the addition of TAR-200, an intravesical targeted releasing system, to checkpoint inhibition as neoadjuvant treatment in patients with muscle-invasive bladder cancer
Presented by: Andrea Necchi, MD, Medical Oncologist, Professor of Oncology, Vita-Salute San Raffaele University, Chief of Genitourinary, Medical Oncology, Fondazione IRCCS Instituto Nazionale dei Tumori, IRCCS San Raffaele Hospital and Scientific Institute, Milan, Italy
Written by: Zachary Klaassen, MD, MSc – Urologic Oncologist, Associate Professor of Urology, Georgia Cancer Center, Wellstar MCG Health, @zklaassen_md on Twitter during the 2024 International Bladder Cancer Network (IBCN) Annual Meeting, Bern, Switzerland, Thurs, Sept 19 – Sat, Sept 21, 2024
Related Content: SunRISe-4 Trial Explores TAR-200 and Cetrelimab Combination for Bladder Cancer Treatment - Andrea Necchi